Contact
searchSearch
HMP Global
Login
Quiz

Chidamide Plus Azacitidine Maintenance Therapy for Acute Myeloid Leukemia

01/12/2026

Recent News

FDA Approval
FDA Approves Simplified Once-Monthly Amivantamab Plus Hyaluronidase Regimen for First-Line EGFR-Mutated Advanced NSCLC
02/18/2026
Stephanie Holland
The FDA has approved a new, simplified once-monthly dosing schedule for amivantamab plus hyaluronidase when administered in combination with lazertinib for the first-line treatment of EGFR-mutated advanced non-small cell lung cancer.
The FDA has approved a new, simplified once-monthly dosing schedule for amivantamab plus hyaluronidase when administered in combination with lazertinib for the first-line treatment of EGFR-mutated advanced non-small cell lung cancer.
The FDA has approved a new,...
02/18/2026
Oncology
FDA Alerts
FDA Grants Breakthrough Therapy Designation to Subcutaneous Amivantamab in HPV-Unrelated Head and Neck Squamous Cell Carcinoma
02/18/2026
Stephanie Holland
Based on data from the phase 1b/2 OrigAMI-4 study, the FDA has granted breakthrough therapy designation to amivantamab plus hyaluronidase for patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma.
Based on data from the phase 1b/2 OrigAMI-4 study, the FDA has granted breakthrough therapy designation to amivantamab plus hyaluronidase for patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma.
Based on data from the phase...
02/18/2026
Oncology
Kelly E. McCann, MD, PhD
News
OLN Great Debates: Navigating Evolving Evidence and Treatment Decisions in Breast Oncology
02/17/2026
Kelly McCann, MD, PhD
For clinicians treating breast cancer, staying current has never been more challenging. New trial data, biomarker-driven strategies, and therapeutic options continue to emerge at a rapid pace, yet translating that evidence into confident,...
For clinicians treating breast cancer, staying current has never been more challenging. New trial data, biomarker-driven strategies, and therapeutic options continue to emerge at a rapid pace, yet translating that evidence into confident,...
For clinicians treating breast...
02/17/2026
Oncology
News
Pirtobrutinib Demonstrates Promise in Relapsed or Refractory Marginal Zone Lymphoma
02/17/2026
Stephanie Holland
Results from the phase 1/2 BRUIN study demonstrated that pirtobrutinib showed promising efficacy and tolerable safety in heavily pretreated patients with relapsed or refractory marginal zone lymphoma.
Results from the phase 1/2 BRUIN study demonstrated that pirtobrutinib showed promising efficacy and tolerable safety in heavily pretreated patients with relapsed or refractory marginal zone lymphoma.
Results from the phase 1/2 BRUIN...
02/17/2026
Oncology
News
Nivolumab Plus Chemotherapy Maintains Survival Advantage in Gastroesophageal Adenocarcinoma
02/12/2026
Stephanie Holland
Long-term follow-up results from the phase 3 CheckMate 649 trial demonstrate that adding nivolumab to chemotherapy continues to prolong survival in previously untreated patients with non-HER2-positive, unresectable or metastatic...
Long-term follow-up results from the phase 3 CheckMate 649 trial demonstrate that adding nivolumab to chemotherapy continues to prolong survival in previously untreated patients with non-HER2-positive, unresectable or metastatic...
Long-term follow-up results from...
02/12/2026
Oncology
News
Iopofosine I 131 Shows Durable Responses in Heavily Pretreated Waldenström Macroglobulinemia
02/12/2026
Emily Estrada
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug...
02/12/2026
Radiopharmaceutical Education Institute
News
Maintenance Palbociclib Extends PFS in HR-Positive, HER2-Positive Metastatic Breast Cancer
02/11/2026
Stephanie Holland
Results from the phase 3 PATINA trial demonstrated that the adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved progression-free survival in HR-positive, HER2-positive metastatic breast cancer.
Results from the phase 3 PATINA trial demonstrated that the adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved progression-free survival in HR-positive, HER2-positive metastatic breast cancer.
Results from the phase 3 PATINA...
02/11/2026
Oncology
News
First-Line Toripalimab Improves PFS in Advanced Melanoma Predominantly of Acral Subtype
02/11/2026
Stephanie Holland
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3...
02/11/2026
Oncology
FDA Approval
FDA Approves Pembrolizumab-Based Regimens for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
02/10/2026
Emily Estrada
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA...
02/10/2026
Oncology
News
Post-Treatment Plasma ctDNA Accurately Identifies Recurrence in Muscle-Invasive Bladder Cancer
02/09/2026
Stephanie Holland
According to results from a retrospective analysis, plasma ctDNA demonstrated strong potential as a biomarker for early detection of metastatic recurrence in patients with muscle-invasive bladder cancer treated with trimodality therapy.
According to results from a retrospective analysis, plasma ctDNA demonstrated strong potential as a biomarker for early detection of metastatic recurrence in patients with muscle-invasive bladder cancer treated with trimodality therapy.
According to results from a...
02/09/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use